Moving averages are one of the core indicators in technical analysis. A Simple Moving Average (SMA) is simply the arithmetic average of stock price over a period. It is calculated by adding a selected range of prices, usually closing prices, and then dividing that figure by the number of time periods in that range.
The 50-Day SMA calculates the average price over 50 days. And the 20-Day SMA and 200-Day SMA calculates the average price over 20 days and 200 days separately.
As of today (2024-05-16), Regado Biosciences's 50-Day SMA is $N/A. It's 20-Day SMA is $N/A and 200-Day SMA is $N/A.
Competitive Comparison of Regado Biosciences's 50-Day SMA
For the Biotechnology subindustry, Regado Biosciences's 50-Day SMA, along with its competitors' market caps and 50-Day SMA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regado Biosciences's 50-Day SMA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Regado Biosciences's 50-Day SMA distribution charts can be found below:
* The bar in red indicates where Regado Biosciences's 50-Day SMA falls into.
Regado Biosciences (NAS:RGDO) 50-Day SMA Calculation
The formula for calculating SMA is:
SMA
=
( P1 + P2 + ... + Pn )
/
n
where:
Pn is the price of the stock at period n.
n is the total number of periods.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regado Biosciences (NAS:RGDO) 50-Day SMA Explanation
Simple Moving Average (SMA) is the arithmetic average of stock price over a period. The 20-Day SMA calculates the average price over 20 days. And the 50-Day SMA and 200-Day SMA calculates the average price over 50 days and 200 days separately. SMAs are often used to determine the price trend direction. A 200-Day SMA is usually a proxy for the long-term trend, while shorter periods indicate short-term trend.
SMA are commonly compared with stock price or different period SMAs to indicate a trading signal. Generally speaking, if the price goes above the SMA, or a short-term SMA crosses above a long-term SMA, an uptrend is expected, investors may want to go long or cover short. Conversely, if the price goes below the SMA, or the short-term SMA crosses below a long-term SMA, a downtrend is expected, investors may want to go short or exit long.
Two popular trading patterns that use SMA include the death cross and a golden cross. A death cross occurs when the 50-day SMA crosses below the 200-day SMA. This is considered a bearish signal, that further losses are in store. The golden cross is a bullish signal which occurs when a short-term SMA crosses above a long-term SMA.
Regado Biosciences 50-Day SMA Related Terms
Thank you for viewing the detailed overview of Regado Biosciences's 50-Day SMA provided by GuruFocus.com. Please click on the following links to see related term pages.
Regado Biosciences (Regado Biosciences) Business Description
Regado Biosciences Inc was incorporated in Delaware under the name Quartet Biosciences, Inc. in December 2001 and changed its name to Regado Biosciences, Inc. in March 2003. It is a biopharmaceutical company. The Company is engaged in the discovery and development of antithrombotic drug systems for acute and sub-acute cardiovascular indications. The Company's product candidates consists of a two-component system: an aptamer and its specific active control agent. The aptamer is administered first and achieves its therapeutic effect within minutes. When the therapeutic effect of the aptamer is no longer needed, the control agent is administered to rapidly and precisely reduce or eliminate it. The level of reduction is determined by the amount of control agent given compared to the aptamer dose. The Company's product candidate, REG1, consists of pegnivacogin, a highly potent and selective anticoagulant, and anivamersen, its specific active control agent. The Company is developing REG1 as an anticoagulant for use in patients with cardiovascular conditions undergoing percutaneous coronary intervention, or PCI, a hospital-based procedure used to mechanically open or widen obstructed coronary arteries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RGDO has been successfully added to your